Effect of high-dose zinc supplementation with oral hypoglycemic agents on glycemic control and inflammation in type-2 diabetic nephropathy patients

Mohd Idreesh Khan, Kauser Usman Siddique, Fauzia Ashfaq, Wahid Ali, Himanshu D Reddy, Arvind Mishra, Mohd Idreesh Khan, Kauser Usman Siddique, Fauzia Ashfaq, Wahid Ali, Himanshu D Reddy, Arvind Mishra

Abstract

Objective: The study aims to evaluate the effect of zinc sulfate on markers of glycemic control, lipid profile and inflammation in type-2 diabetes with microalbuminuria patients.

Materials and methods: Type-2 diabetes with microalbuminuria patients on oral hypoglycemic agents (OHA) and angiotensin converting enzyme (ACE) inhibitors were selected and divided into 2 groups: One group (n = 27) continued with OHA alone, second group (n = 27) was on OHA and in addition 50 mg elemental zinc as zinc sulphate supplementation for 12 weeks. Fasting, post-prandial blood glucose, glycosylated hemoglobin, lipid profiles, inflammatory marker hs-CRP and urine microalbumin were measured.

Results: There were no significant differences in biochemical status among groups at baseline. After receiving zinc, the mean fasting blood glucose (FBS), post-prandial blood glucose (PPBS) and glycosylated hemoglobin (HbA1c) were decreased significantly (P = 0.0001). Significant decrease was observed in TG (P = 0.002) and VLDL-cholesterol (P = 0.002), whereas there was no significant decrease in TC and LDL-cholesterol. The high-density lipoprotein (HDL) cholesterol was significantly (P = 0.0001) increased from baseline. Zinc supplementation had significant effects in decreasing serum hs-CRP from 10.51 ± 1.68 mg/L to 7.75 ± 1.56 mg/L (P = 0.0001) and microalbumin level from 146.87 ± 30.83 mg/day to 80.70 ± 33.99 mg/day (P = 0.0001). There were no significant changes in the levels of all these parameters in OHA group.

Conclusion: Our results conclude that supplementation of zinc improved the effectiveness of OHA and may be beneficial in decreasing blood glucose, TG, urinary albumin excretion and inflammation in diabetic nephropathy patients and thus reducing the risk of complications.

Keywords: Glycemic control; inflammation; microalbuminuria; type-2 diabetes; zinc sulphate.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Agarwal SK, Dash SC. Spectrum of renal diseases in Indian adults. J Assoc Physicians India. 2000;48:594–600.
    1. American Diabetes Association. Nephropathy in diabetes (Position Statement) Diabetes Care. 2004;27:79–83.
    1. Ladeia AM, Stefanelli E, Ladeia-Frota C, Moreira A, Hiltner A, Adan L. Association between elevated serum C-reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care. 2006;29:424–6.
    1. Scheid DC, McCarthy LH, Lawler FH, Hamm RM, Reilly KE. Screening for microalbuminuria to prevent nephropathy in patients with diabetes: A systematic review of the evidence. J Fam Pract. 2001;50:661–8.
    1. Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The insulin resistance atherosclerosis study. Kidney Int. 2000;58:1703–10.
    1. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157–65.
    1. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003;42:53–61.
    1. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, et al. C-reactive protein and soluble vascular cell adhesion -1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2002;22:593–8.
    1. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int. 2001;59:260–9.
    1. Wijesekara N, Chimienti F, Wheeler MB. Zinc, a regulator of islet function and glucose homeostasis. Diabetes Obes Metab. 2009;11:202–14.
    1. Hennig B, Meerarani P, Toborek M, McClain CJ. Antioxidant-like properties of zinc in activated endothelial cells. J Am Coll Nutr. 1999;18:152–8.
    1. Prasad AS, Bao B, Beck FW, Kucuk O, Sarkar FH. Antioxidant effect of zinc in humans. Free Radic Biol Med. 2004;37:1182–90.
    1. Marjani A. Plasma lipid peroxidation, zinc and erythrocyte Cu- Zn superoxide dismutase enzyme activity in patients with type 2 diabetes mellitus in Gorgan city (south east of the Caspian Sea) Internet J Endocrinol. 2005;2:1540–2606.
    1. Lee JH, Lee HJ, Lee IK, Yoon JS. Zinc and copper status of middle- and old-aged woman in type 2 diabetes. Korean J Nutr. 2005;38:56–66.
    1. Yoon JS, Lee JH. A suggestion to improve zinc status of type 2 diabetic women: Relation among zinc, protein and phytate intake. J Korean Diet Assoc. 2007;13:301–10.
    1. Gunasekara P, Hettiarachchi M, Liyanage C, Lekamwasam S. Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes. Diabetes Metab Syndr Obes. 2011;4:53–60.
    1. Afkhami-Ardekani M, Karimi M, Mohammadi SM, Nourani F, Soheilykhah S. Comparison of the effects of sodium metavanadate and zinc sulfate supplementation on lipid and glucose in patients with type 2 diabetes. Iran J Diabetes Obes. 2009;1:22–29.
    1. Roussel AM, Kerkeni A, Zouari N, Mahjoub S, Matheau JM, Anderson RA. Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. J Am Coll Nutr. 2003;22:316–21.
    1. Partida-Hernandez G, Arreola F, Fenton B, Cabeza M, Roman-Ramos R, Revilla-Monsalve MC. Effect of zinc replacement on lipids and lipoproteins in type 2-diabetic patients. Biomed Pharmacother. 2006;60:161–8.
    1. Ghayour-Mobarhan M, Taylor A, New SA, Lamb DJ, Ferns GA. Determinants of serum copper, zinc and selenium in healthy subjects. Ann Clin Biochem. 2005;42:364–75.
    1. Garber AJ, Karlsson FO. Treatment of dyslipidemia in diabetes. Endocrinol Metab Clin North Am. 2001;30:991–1010.
    1. Hennig B, Toborek M, McClain CJ. High-energy diets, fatty acids and endothelial cell function: Implication for atherosclerosis. J Am Coll Nutr. 2001;20:91–105.
    1. Bao B, Prasad AS, Beck FW, Fitzgerald JT, Snell D, Bao GW, et al. Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: A potential implication of zinc as an atheroprotective agent. Am J Clin Nutr. 2010;91:1634–41.
    1. Prasad AS, Beck FW, Bao B, Fitzgerald JT, Snell DC, Steinberg JD, et al. Zinc supplementation decreases incidence of infections in the elderly: Effect of zinc in generation of cytokines and oxidative stress. Am J Clin Nutr. 2007;85:837–44.
    1. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferators-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26:28–40.
    1. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048–54.
    1. Reiterer G, Toborek M, Hennig B. Peroxisome proliferator activated receptors alpha and gamma require zinc for their anti-inflammatory properties in porcine vascular endothelial cells. J Nutr. 2004;134:1711–5.
    1. Parham M, Amini M, Aminorroaya A, Heidarian E. Effect of zinc supplementation on microalbuminuria in patients with type 2 diabetes: A double blind, randomized, placebo controlled, cross-over trial. Rev Diabet Stud. 2008;5:102–9.
    1. Farvid MS, Jailali M, Siassi F, Hosseini FM. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care. 2005;28:2458–64.
    1. Bonnefont-Rousselot D. The role of antioxidant micronutrientents in the prevention of diabetic complications. Treat Endocrinol. 2004;3:41–52.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner